TBPH (Theravance Biopharma, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by TBPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-08-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | — | — |
| 2026-08-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | — | — |
| 2026-08-24 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-08-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | — | — |
| 2026-07-08 | Eli Samaha | 10%+ Owner | Sell | — | — |
| 2026-07-01 | Eli Samaha | 10%+ Owner | Sell | — | — |
| 2026-06-23 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | A | — | — |
| 2026-06-17 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | — | — |
| 2026-06-16 | SUSANNAH GRAY | Director | A | — | — |
| 2026-06-16 | DEEPIKA PAKIANATHAN | Director | A | — | — |
| 2026-06-16 | Alsup Laurie Smaldone | Director | A | — | — |
| 2026-06-16 | DEAN J MITCHELL | Director | A | — | — |
| 2026-06-16 | Donal O'Connor | Director | A | — | — |
| 2026-05-22 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | — | — |
| 2026-05-22 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-05-22 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-05-22 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | — | — |
| 2026-05-22 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | — | — |
| 2026-04-03 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-04-03 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | A | — | — |
| 2026-04-03 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | A | — | — |
| 2026-04-03 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-03-18 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | — | — |
| 2026-02-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | — | — |
| 2026-02-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | — | — |
| 2026-02-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | — | — |
| 2026-02-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | — | — |
| 2026-02-24 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-12-05 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | — | — |
| 2025-12-01 | ERAN BROSHY | Director | Sell | — | — |
| 2025-11-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | — | — |
| 2025-11-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-11-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | — | — |
| 2025-11-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | — | — |
| 2025-11-21 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-11-14 | ERAN BROSHY | Director | Sell | — | — |
| 2025-11-13 | ERAN BROSHY | Director | Sell | — | — |
| 2025-08-22 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-08-22 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | — | — |
| 2025-08-22 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-08-22 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | — | — |
| 2025-08-22 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | — | — |
| 2025-07-16 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | — | — |
| 2025-06-25 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | G | — | — |
| 2025-06-17 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | G | — | — |
| 2025-06-04 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | — | — |
| 2025-05-22 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | — | — |
| 2025-05-22 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | — | — |
| 2025-05-22 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 9,167,489 | — |
| — | CHIEF EXECUTIVE OFFICER | 1,634,422 | — |
| — | SVP, CHIEF BUSINESS OFFICER | 429,783 | — |
| — | SVP, CHIEF FINANCIAL OFFICER | 384,714 | — |
| — | SVP, PROD STRAT & COMM PLNG | 380,123 | — |
| — | SVP, GEN COUNSEL AND SECRETARY | 355,168 | — |
| — | SVP & CHIEF FINANCIAL OFFICER | 336,841 | — |
| — | SVP, RESEARCH & TRANSL SCIENCE | 330,752 | — |
| — | SVP, RESEARCH & DEVELOPMENT | 314,915 | — |
| — | SVP, Research & Development | 288,111 | — |
| — | EVP, Gen. Counsel, Secretary | 277,831 | — |
| — | SVP, Research | 259,900 | — |
| — | Chief Medical Officer | 242,499 | — |
| — | SVP, TECHNICAL OPERATIONS | 235,524 | — |
| — | Sr. VP, Technical Operations | 234,071 | — |
| — | SVP, COMM & MEDICAL AFFAIRS | 226,790 | — |
| — | SVP, DEV & HEAD OF IRE OFFICE | 189,826 | — |
| — | Sr VP, Chief Comm. Officer | 182,731 | — |
| — | SVP, Chief Financial Officer | 157,657 | — |
| — | Director | 115,589 | — |
| — | PRESIDENT, TBIL | 110,319 | — |
| — | Director | 97,213 | — |
| — | SVP, Corp Dev & Strategy | 97,198 | — |
| — | Director | 80,989 | — |
| — | Director | 80,213 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TBPH quote page; the site-wide leaderboard is on the insider transactions hub.